Every patient’s journey with multiple sclerosis is different.
Multiple sclerosis, a disease of the brain and spinal cord, can be difficult to diagnose and symptoms may range from body weakness to vision difficulty. Many times, patients may be evaluated for a range of other conditions, before MS is finally determined to be the root cause of their symptoms.Our program offers state-of the-art diagnostic imaging studies and comprehensive subspecialty care for patients including:
We provide these treatment options for patients with MS:
The ARISE clinical trial is evaluating the safety and efficacy of an investigational drug to determine its effects on daytime sleepiness, tiredness, fatigue, and routine functioning in people with Idiopathic Hypersomnia and Narcolepsy without cataplexy.
For more information on this study please visit the website at: http://www.arisestudies.com/index.html
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
The purpose of the clinical
trial CHORDS is to evaluate the effectiveness and safety of the investigational
drug Ocrelizumab in patients with relapsing remitting multiple sclerosis who
have had a suboptimal response to an adequate course of disease-modifying
treatments.
For more information on this
study please visit the website at: http://www.gene.com/media/press-releases/14609/2015-10-08/genentechs-ocrelizumab-first-investigati
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
This study is collecting information in safety and documenting the drug utilization of Tecfidera (Dimethyl Fumarate) when used in routine medical practice in the treatment of MS.
For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02047097
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
This clinical trial is a treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive MS.
For more information on this study please visit the website at: www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
This is a group study to
evaluate the efficacy and safety of Ocrelizumab in comparison to interferon
Beta-1A (Rebif) in patients with relapsing MS.
For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT01412333
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
This is a long-term follow-up study for MS patients who have completed the alemtuzumab Extension Study (CAMMS03409).
For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02167945
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
This is a phase IIIb, study to evaluate the effects of Orcelizumab on immune responses in patients with relapsing forms of MS.
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
Open
label study to evaluate safety and effectiveness of ocrelizumab in
progressive forms of MS. https://clinicaltrials.gov/ct2/show/NCT01412333
To
enroll in this study at USF please contact Angela Aungst at (813)974-6378
Phase 2 study, to evaluate efficacy and safety of BIIB033 as add-on therapy to anti-disease-modifying therapies. To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks and to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement.
For more information please visit the website at: https://clinicaltrials.gov/ct2/show/NCT03222973
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
Testing safety and efficacy of MD1003 in progressive multiple sclerosis. The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
For more information please visit the website: https://clinicaltrials.gov/ct2/show/NCT02936037
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo. The blinded treatment period will be at least 120 weeks, followed by an Open Label Extension (OLE) treatment for participants in both groups who in the opinion of the investigator could benefit from further or newly initiated ocrelizumab treatment. Unless terminated early, all participants will continue their treatment with open-label ocrelizumab until the last participant who entered the OLE phase reaches 4 years of open-label ocrelizumab treatment.
For more information please visit the website at: https://clinicaltrials.gov/ct2/show/NCT01194570
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
Double masked, placebo controlled study with open label period to evaluate and compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.
For more information please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02200770
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
Double blind, placebo controlled study to assess efficacy and safety of HP Acthar gel in RRMS.
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
Prospective,
post authorization safety study to evaluate long term safety profile of
Lemtrada
To
enroll in this study at USF please contact Angela Aungst at (813)974-6378
Study for RRMS/PPMS patients switching therapy, to assess relationship between cognitive function and brain atrophy.
To enroll in this study at USF please contact Angela Aungst at (813)974-6378
Phase 3, study of treatment effects of ublituximab in MS.
To enroll in this study at USF please contact Angela Aungst at (813)974-6378